Astellas wins FDA approval of eye disease drug Izervay and may have edge in market battle with Apellis
Fierce Pharma
AUGUST 7, 2023
Less than four months after Astellas’ $5.9 billion buyout of eye disease specialist Iveric Bio, the deal is already making the Tokyo-based company look visionary. Less than four months after Astellas’ $5.9
Let's personalize your content